The Genome Bought on the Open Market

The Genome Bought on the Open Market

A single company quietly assembled DNA profiles from fifteen million consumers who spat into a tube for fun, then the company filed for bankruptcy. This is the story of how genetic data becomes an asset in a court-approved sale, and what a future buyer could do with the blueprint of people who never consented to being sold.

Listen in the Fylom app.

Show notes

Genetic profiles are treated as liquid assets that can be sold like office furniture during corporate bankruptcy.

The fifteen million person database was valued as a searchable library for pharmaceutical drug discovery partnerships.

A three hundred five million dollar sale allowed genetic data transfer without requiring new user consent.

Whole genome sequences cannot be truly anonymized because DNA acts as a permanent and unchangeable identifier.

Genetic data sharing compromises the privacy of biological relatives who never signed a waiver.

Consumer genetic testing exists in a legal gray zone where standard health privacy laws do not apply.

In this episode
  1. 01Intro1 min
  2. 02The Fifteen Million Person Asset2 min
  3. 03Liquidation of the Genome3 min
  4. 04The Myth of Anonymity3 min
  5. 05The Buyer's Toolkit2 min
  6. 06Outro1 min
Sources
Your turn

Fylom generates episodes like this on any topic you're curious about.

Fylom episodes are researched, written, and voiced by AI. Automated checks help catch inaccuracies, but episodes aren't reviewed by a human and AI can still get things wrong. Treat them as a starting point, not a source of record — more in our accuracy disclaimer.

The Genome Bought on the Open Market — Fylom